TIPARP Inhibitor Compounds for PARP1/2-Sparing Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for compounds that selectively inhibit TIPARP with high potency and selectivity while minimizing the inhibition of other PARP enzymes to avoid systemic cytokine production and side effects.
Innovation Solution
Development of compounds of Formula (I) with specific structural features, including L, R1, R2, R3, R4, and Z, which exhibit high potency and selectivity for TIPARP inhibition, reducing off-target effects on other PARP enzymes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If compounds are designed to inhibit TIPARP with high potency, then anti-tumor immune response is enhanced, but off-target inhibition of other PARP enzymes occurs causing systematic cytokine production and side effects
Solution Approach 1:
The patent applies local quality by designing specific structural features at particular positions of the compound molecule. The substituents R1-R6 are positioned at specific locations on the core structure, with each position having defined chemical group options that collectively achieve TIPARP selectivity while minimizing off-target effects on other PARP enzymes
Solution Approach 2:
The patent employs parameter changes by systematically varying chemical parameters such as substituent types (R1-R6), linkage structures (L1-L6), and molecular configuration to optimize the balance between TIPARP inhibition potency and selectivity. This includes adjusting hydrophobicity, steric bulk, and electronic properties at different molecular positions
2Quantity of substance
If compounds inhibit TIPARP at low concentrations, then therapeutic efficacy is improved, but off-target activity on other PARP enzymes increases causing side effects
Solution Approach 1:
The patent applies partial action by designing compounds that achieve sufficient TIPARP inhibition at therapeutic concentrations without excessive inhibition of other PARP enzymes. The molecular structure is optimized to provide just enough affinity for TIPARP to achieve therapeutic effect while maintaining selectivity that prevents off-target effects at clinically relevant doses
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present disclosure provides for compounds of Formula (I), and pharmaceutically acceptable salts thereof, that inhibit the activity of TIPARP, wherein the variables have any of the values defined in the specification.